Kim, HoUng
Alten, Rieke http://orcid.org/0000-0002-3395-4412
Avedano, Luisa
Dignass, Axel http://orcid.org/0000-0002-9724-054X
Gomollón, Fernando
Greveson, Kay
Halfvarson, Jonas http://orcid.org/0000-0003-0122-7234
Irving, Peter M.
Jahnsen, Jørgen http://orcid.org/0000-0002-0419-2914
Lakatos, Péter L.
Lee, JongHyuk
Makri, Souzi
Parker, Ben
Peyrin-Biroulet, Laurent
Schreiber, Stefan
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Westhovens, Rene http://orcid.org/0000-0002-3432-3073
Danese, Silvio
Jeong, Ji Hoon http://orcid.org/0000-0001-8257-403X
Funding for this research was provided by:
Celltrion Healthcare
Article History
First Online: 30 January 2020
Change Date: 2 June 2020
Change Type: Correction
Change Details: The affiliation of the corresponding author Silvio Danese, which currently reads.
Compliance with Ethical Standards
:
: Celltrion Healthcare Co., Ltd provided funding for medical writing support for this article.
: HK is employed by and holds stock options in Celltrion Healthcare Co., Ltd. LA has received financial support from Biogen for lectures; grants have been awarded to the European Federation of Crohn’s & Ulcerative Colitis Associations (for projects, advocacy activities, surveys) from Atlantic, AbbVie, Biogen, Celgene, Celltrion, Merck-MSD, Ferring, Janssen, Mundipharma, Otsuka, Pfizer, Shire, Takeda, Vifor, and Philips Morris International Foundation. AD has served as consultant for AbbVie, Celgene, Janssen, MSD, Pfizer, Roche, Sandoz/Hexal, Takeda, and Vifor; received payment for development of educational presentations from Falk Foundation, Ferring, Tillotts, and Takeda; received speaker fees from AbbVie, Falk Foundation, Ferring, Janssen, MSD, Pfizer, Vifor, and Takeda; received manuscript fees from Thieme and Wiley; and received research grants from Institut für Gemeinwohl and Stiftung Leben mit Krebs. FG has received financial support from AbbVie, Janssen, MSD, and Takeda for lectures and travel to scientific meetings. JH has received research grants from Janssen, MSD, and Takeda; served as a consultant and/or an advisory board member for AbbVie, Celgene, Celltrion, Ferring, Hospira, Janssen, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Tillots Pharma, and Vifor Pharma; and served as a speaker for AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Novartis, Pfizer, Sandoz, Shire, Takeda, Tillotts Pharma, and Vifor Pharma. PMI has received honoraria for acting in an advisory capacity from AbbVie, Celgene, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Samsung Bioepis, Sandoz, Takeda, Topivert, VH2, Vifor, and Warner Chilcott; received speaker fees from AbbVie, Falk Pharma, Ferring, Janssen, MSD, Pfizer, Sandoz, Shire, Takeda, Tillotts, and Warner Chilcott; and received research funding from MSD, Pfizer, and Takeda. JJ has served as a speaker, consultant, or advisory board member for AbbVie, Astro Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, and Sandoz. PLL has received consulting fees or lecture support from AbbVie, Celgene, Celltrion, Ferring, MSD, Pfizer, Roche, and Takeda and unrestricted research support from AbbVie, Pfizer, and Takeda. BP has received honoraria and speaker fees from AbbVie, AstraZeneca, Celltrion, GSK, Lilly, Pfizer, Roche, and UCB. LP-B has received consulting fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Enterome, Ferring, Genentech, Gilead, Index Pharmaceuticals, Janssen, Lilly, MSD, Nestle, Oppilan Pharma, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Tillotts, and Vifor; payment for lectures, including service on speakers bureaus, from AbbVie, Biogen, Celltrion, Ferring, Hikma, Janssen, MSD, Pfizer, Roche, Samsung Bioepis, Takeda, and Tillotts; grant/research support from AbbVie, MSD, and Takeda; and stock options from CT-SCOUT. Stefan Schreiber has received personal fees for participation on advisory boards from AbbVie, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, IMAB, Falk, Fresenius, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Takeda, and Theravance. Steven Simoens has conducted biosimilar research sponsored by Hospira (now Pfizer); was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, MSD, and Pfizer; has participated in an advisory board meeting for Pfizer; and currently works with Amgen, Celltrion, Mundipharma, and Pfizer as a consultant to carry out biosimilar research. RW has acted as a principal investigator and advisor for Celltrion and Galapagos/Gilead and has given lectures for Celltrion. SD has received consulting fees or honorarium from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring Pharmaceuticals Inc., Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, and Pfizer. RA, KG, JHJ, JL, and SM have no conflicts of interest that are directly relevant to the content of this article.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: This article does not contain any studies with human participants or animals performed by any of the authors.